Healthcare
Live Price
Offline$78.98
+0.57% today
1Y Change
+59.23%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PTC Therapeutics, Inc. (PTCT) is a Healthcare stock with a market cap of $5.40B and listed on NASDAQ. The stock last traded around $78.98 and up 59.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +114.5%, EPS growth of +281.4%, a dividend yield of 0.0%. What stands out right now is revenue +114.5%, EPS +281.4%, free cash flow +486.0% with operating margin 49.5% and ROIC 37.4%. Valuation is more restrained than many high-expectation growth names at P/E 7.7 and price/sales 3.1. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines PTCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTCT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PTCT Max Drawdown
-27.17%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PTCT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$538.6M
-22.9% YoY
FY Net Income
-$523.9M
+6.3% YoY
Free Cash Flow
-$336.7M
+33.9% YoY
Revenue Growth
+114.5%
EPS Growth
+281.4%
Gross Margin
91.0%
Net Margin
39.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.7B | 807M | 938M | 699M | 539M |
| Gross Profit | 1.7B | 749M | 872M | 654M | 506M |
| Operating Income | 857M | -303M | -440M | -447M | -374M |
| EBITDA | 888M | -120M | -330M | -368M | -368M |
| Net Income | 683M | -363M | -627M | -559M | -524M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 985M | 780M | 594M | 280M | 190M |
| Total Assets | 2.9B | 1.7B | 1.9B | 1.7B | 1.9B |
| Total Liabilities | 3.1B | 2.8B | 2.7B | 2.1B | 1.9B |
| Shareholder Equity | -205M | -1.1B | -819M | -347M | 1M |
| Total Debt | 492M | 2.5B | 2.2B | 1.5B | 1.3B |
| Net Debt | -492M | 1.7B | 1.6B | 1.2B | 1.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
251M
+29.5% YoY
Capital Expenditures
85M
+44.0% YoY
Free Cash Flow
337M
+33.9% YoY
Key ratios
Gross Margin
91.0%
Operating Margin
49.5%
Net Margin
39.4%
ROE
-362.4%
Debt / Equity
-2.40x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.